Doug Coyle1, Yoo-Joung Ko2, Kathryn Coyle3, Ronak Saluja4, Keya Shah5, Kelly Lien4, Henry Lam4, Kelvin K W Chan6. 1. University of Ottawa, Ottawa, Ontario, Canada; Health Economics Research Group, Brunel University, Uxbridge, UK. 2. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada. 3. Health Economics Research Group, Brunel University, Uxbridge, UK. 4. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 5. Queen's University, Kingston, Ontario, Canada. 6. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada. Electronic address: kelvin.chan@sunnybrook.ca.
Abstract
OBJECTIVES: To assess the cost-effectiveness of gemcitabine (G), G + 5-fluorouracil, G + capecitabine, G + cisplatin, G + oxaliplatin, G + erlotinib, G + nab-paclitaxel (GnP), and FOLFIRINOX in the treatment of advanced pancreatic cancer from a Canadian public health payer's perspective, using data from a recently published Bayesian network meta-analysis. METHODS: Analysis was conducted through a three-state Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens. Estimates of health care costs were obtained from local providers, and utilities were derived from the literature. The model estimates the effect of treatment regimens on costs and quality-adjusted life-years (QALYs) discounted at 5% per annum. RESULTS: At a willingness-to-pay (WTP) threshold of greater than $30,666 per QALY, FOLFIRINOX would be the most optimal regimen. For a WTP threshold of $50,000 per QALY, the probability that FOLFIRINOX would be optimal was 57.8%. There was no price reduction for nab-paclitaxel when GnP was optimal. CONCLUSIONS: From a Canadian public health payer's perspective at the present time and drug prices, FOLFIRINOX is the optimal regimen on the basis of the cost-effectiveness criterion. GnP is not cost-effective regardless of the WTP threshold.
OBJECTIVES: To assess the cost-effectiveness of gemcitabine (G), G + 5-fluorouracil, G + capecitabine, G + cisplatin, G + oxaliplatin, G + erlotinib, G + nab-paclitaxel (GnP), and FOLFIRINOX in the treatment of advanced pancreatic cancer from a Canadian public health payer's perspective, using data from a recently published Bayesian network meta-analysis. METHODS: Analysis was conducted through a three-state Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens. Estimates of health care costs were obtained from local providers, and utilities were derived from the literature. The model estimates the effect of treatment regimens on costs and quality-adjusted life-years (QALYs) discounted at 5% per annum. RESULTS: At a willingness-to-pay (WTP) threshold of greater than $30,666 per QALY, FOLFIRINOX would be the most optimal regimen. For a WTP threshold of $50,000 per QALY, the probability that FOLFIRINOX would be optimal was 57.8%. There was no price reduction for nab-paclitaxel when GnP was optimal. CONCLUSIONS: From a Canadian public health payer's perspective at the present time and drug prices, FOLFIRINOX is the optimal regimen on the basis of the cost-effectiveness criterion. GnP is not cost-effective regardless of the WTP threshold.
Authors: Mahdi Gharaibeh; Ali McBride; David S Alberts; Brian Erstad; Marion Slack; Nimer Alsaid; J Lyle Bootman; Ivo Abraham Journal: Pharmacoeconomics Date: 2018-11 Impact factor: 4.981
Authors: Michael J Raphael; William Raskin; Steven Habbous; Xiaochen Tai; Jaclyn Beca; Wei F Dai; Jessica Arias; Leta Forbes; Scott Gavura; James J Biagi; Craig C Earle; Kelvin K W Chan Journal: JAMA Netw Open Date: 2021-11-01
Authors: Andrew D Scarffe; Christopher J Licskai; Madonna Ferrone; Kevin Brand; Kednapa Thavorn; Doug Coyle Journal: Cost Eff Resour Alloc Date: 2022-08-12
Authors: Vanessa Arciero; Jin Luo; Ambica Parmar; Wei Fang Dai; Jaclyn M Beca; Michael J Raphael; Wanrudee Isaranuwatchai; Steven Habbous; Mina Tadrous; Craig C Earle; Jim J Biagi; Nicole Mittmann; Jessica Arias; Scott Gavura; Kelvin K W Chan Journal: JNCI Cancer Spectr Date: 2022-07-01